The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research, focusing on uncovering the causes of cancer and reprogramming cancer cells. Our mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer. This research is the basis for developing minimally toxic treatments for patients.

Through our collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since our inception in 1976, The Foundation has awarded approximately $90 million to support the work of more than 200 researchers across the globe.
Dear Friend,

The SWCRF’s 40th anniversary last year presented a good opportunity to take stock of the major changes in how we treat cancer patients today. Progress can be best described as incremental, a stepwise translation of research to clinical trials with sometime dramatic clinical impact. Cancer treatment has evolved into a more personalized selection of treatment options based on understanding the nature of the cancer using technology that has evolved during the past ten years. Although traditional chemotherapy remains the mainstay of treatment, it is no longer necessary to apply the concept of treating fire with fire to cancer therapy. During the last ten years more anti-cancer drugs have been approved by the FDA than in the past 50 years. These drugs are less toxic, based on basic research described many years ago, and are beginning to replace traditional chemotherapy. The death rates for most cancers have been considerably decreased, however, at great cost and uncertainty remains. It is amazing to see patients who have extraordinary responses to these new treatments such as former president Jimmy Carter, who reportedly had melanoma metastasis in the brain and responded to a novel treatment.

The SWCRF can be proud that for 40 years we have taken this approach to cancer therapy. As described in this annual report, the differentiation therapy of acute promyelocytic leukemia (APL), which resulted in a 95 percent cure rate, is the antecedent to today’s new approach to treatment. With this type of therapy, there is minimal damage to normal cells so the potential for development of a new cancer is markedly diminished. This requires collaboration to leverage the talents of many investigators to target a common goal of creating scientifically based, minimally toxic therapies. The international collaborations encouraged by the SWCRF have initiated clinical trials by SWCRF investigators working in Tel Aviv, Chicago, Houston and Boston, to name but a few. This offers hope to all that cancer can be a manageable disease without losing quality of life due to the toxicity of most treatments.

Cancer incidence continues to rise around the world although mortality rates are decreasing. This is due to the growing incidence of cancer in our aging population which is predicted to increase dramatically around the world. The SWCRF is taking a leadership role in bringing together scientists working in aging and cancer to confront this problem. We have initiated collaborations with the National Cancer Institute, the National Institute on Aging and other Foundations to build a consortium with the capacity to give us insight on the management of this growing epidemic. Today, the SWCRF Institute Without Walls is in a growth phase anchored by our new Executive Director, William Sullivan, a strong Foundation staff, a dedicated Board of Directors and our devoted donors. Together we will continue to play an important role in making cancer a curable disease.

Remember, we can’t do this without you.

Sincerely,

Michael Nierenberg
Chairman

Samuel Waxman, M.D.
Founder and CEO

Spencer Waxman
President

ANNUAL REPORT 2016
On May 18, philanthropist Andrea Stark hosted the third annual Collaborating for a Cure Luncheon to benefit SWCRF. The fundraiser featured a presentation of the Fall 2016 Oscar de la Renta collection.

The twelfth annual A Hamptons Happening raised $300,000 for research on July 9. The honorees were Deirdre Quinn, Sandra Lee and Jayma Cardoso.

The SoHo concept store of Lafayette 148 New York hosted a shopping night in support of SWCRF’s Pay It Forward program on September 28. The event was hosted by Dan Lawson, stylist for the CBS series “The Good Wife.”

The 19th annual Collaborating for a Cure Gala introduced the SWCRF Vince Camuto Memorial Cancer Research Program and raised $2.5 million on November 10. The night featured a performance by Roger Daltrey of The Who with a surprise appearance by Willie Nile.

On May 18, philanthropist Andrea Stark hosted the third annual Collaborating for a Cure Luncheon to benefit SWCRF. The fundraiser featured a presentation of the Fall 2016 Oscar de la Renta collection.

The twelfth annual A Hamptons Happening raised $300,000 for research on July 9. The honorees were Deirdre Quinn, Sandra Lee and Jayma Cardoso.

The SoHo concept store of Lafayette 148 New York hosted a shopping night in support of SWCRF’s Pay It Forward program on September 28. The event was hosted by Dan Lawson, stylist for the CBS series “The Good Wife.”

The 19th annual Collaborating for a Cure Gala introduced the SWCRF Vince Camuto Memorial Cancer Research Program and raised $2.5 million on November 10. The night featured a performance by Roger Daltrey of The Who with a surprise appearance by Willie Nile.
The Samuel Waxman Cancer Research Foundation (SWCRF) has made great strides in the development of its new Aging and Cancer research initiative. The program is the brainchild of SWCRF Founder and CEO Samuel Waxman, M.D., who identified an unmet need for research on the causal roles of genetic and environmental factors in the rising incidence of cancer as people age. Dr. Waxman appeared on the business news cable program Varney & Co. on June 7 to discuss this trend.

Cancer is a disease of aging and as people are living longer, global populations are projected to increase dramatically. The U.S. Census Bureau estimates that the population of people over 65 will reach 83.7 million in 2050, almost double its 2012 population of 43.1 million. As this population booms, so will the burden of cancer. According to the National Cancer Institute (NCI), cancer incidence increases dramatically after age 40 and the median age of people diagnosed with cancer in the United States is 65. Americans diagnosed with the most prevalent cancer types are, on average, over the age of 50. Despite these alarming statistics, research that focuses on the connections between aging and cancer is severely underfunded.

To address this growing health threat, the SWCRF is spearheading The Partnership for Aging & Cancer Research, a breakthrough collaboration among leading research and funding organizations to build a multyear funding program that will pool the expertise of leading scientists in cancer and aging. The SWCRF has reached an agreement with the NCI in which the NCI will contribute three times the amount committed by the SWCRF. The SWCRF has also approached the American Federation for Aging Research (AFAR) and the National Institute on Aging (NIA) to join the Partnership, which aims to launch with a $3 million budget to fund seven collaborating research teams over two years beginning in 2018. This is a novel synergistic collaboration between public foundations, philanthropists and government agencies: a “Moonshot” initiative.

“The growing incidence of cancer as people age is not a threat relegated to older people,” says Dr. Waxman. “Our program targets the genetic damage that builds up over time throughout a person’s life so it benefits children and adults of all ages. As our children are expected to live longer lives, their risk of getting cancer will be greater than ours.”

Inspired by discussions among 15 leading cancer and aging researchers who participated in the SWCRF Aging & Cancer Workshop last year, research by this program’s grantees would address how lifespan affects cancer development and how scientists can use their deepening knowledge of aging to enhance prevention or treatment of cancer. The initiative’s long-term goal is to build a $20 million funding program.

---

**The Samuel Waxman Cancer Research Foundation appoints William T. Sullivan Executive Director**

The Samuel Waxman Cancer Research Foundation (SWCRF) has appointed William T. Sullivan to the position of Executive Director. An accomplished leader with a track record of dramatically improving the efficiency and fundraising of high-profile nonprofit organizations, Mr. Sullivan brings more than 30 years of experience to his new post.

“The Board of Directors of the Samuel Waxman Cancer Research Foundation and I are delighted to welcome William Sullivan to our organization as Executive Director,” said Samuel Waxman, M.D., founder and CEO of the Samuel Waxman Cancer Research Foundation. “His expertise in improving organizational infrastructure and maximizing fundraising in the nonprofit sector will greatly advance our mission to fund innovative epigenetic research to eradicate cancer.”

“I have always admired the work of the Samuel Waxman Cancer Research Foundation and its excellent reputation,” said William T. Sullivan. “It will be my honor to work with Dr. Waxman, the Board, the staff, and the Foundation’s donors to further the important work of this noble organization.”

Mr. Sullivan is a multifaceted strategic leader well regarded for his long tenures at Ronald McDonald House New York and the Greater New York Councils, Boy Scouts of America. He served as President and Chief Executive Officer of Ronald McDonald House New York for ten years during which the charity’s annual operating budget tripled to $20 million and net assets grew to $122 million. Under Mr. Sullivan’s leadership, the organization’s volunteer leadership grew from 200 to over 850 active volunteers. Prior to his time at Ronald McDonald House, he had a 20-year tenure at the Greater New York Councils, Boy Scouts of America, rising through the ranks to the position of Chief Operating Officer. Most recently, Mr. Sullivan served as Director of Campaign Fundraising for New York City mayoral candidate Paul J. Massey, Jr.
Our funded research has led to new clinical trials currently in process at several research institutes for potential treatments for liver, ovarian, breast and pediatric cancer.

**PROOF OF PRINCIPLE**

Our philosophy of reprogramming cancer cells to function normally through differentiation led to a breakthrough treatment for acute promyelocytic leukemia (APL). The treatment, developed through collaboration between SWCRF founder and CEO Samuel Waxman, M.D., and researchers from the Shanghai Institute of Hematology, dramatically improved the survival rate of APL, which had a 100 percent fatality rate, to 95 percent, saving countless lives. It remains the course of treatment for the disease.

**OUR INVESTMENT IN RESEARCH**

- We support leading researchers in a wide range of cancer categories.
- Since 1976, we’ve awarded $90 million to over 200 researchers worldwide.
- In the past ten years alone we’ve invested more than $23 million in cancer research.

**OUR FUNDED SITES**

- Baylor College of Medicine
- Dana Farber Cancer Institute
- Dartmouth Medical School
- Icahn School of Medicine at Mount Sinai
- Jewish General Hospital/McGill University
- Johns Hopkins University
- Massachusetts General Hospital
- MD Anderson Cancer Center
- Memorial Sloan-Kettering Cancer Center
- Northwestern University
- NYU Langone Medical Center
- Ontario Cancer Institute
- Salk Institute
- Shanghai Institute of Hematology
- Stanford University School of Medicine
- Tel Aviv University
- University of California, San Francisco
- University of Florida Health
- University of North Carolina, Chapel Hill
- University of Pennsylvania
- University of Toronto
- University of Utah
- Weill Cornell Institute for Biomedical Research

**OUR IMPACT**

**CLINICAL TRIALS**

Our funded research has led to new clinical trials currently in process at several research institutes for potential treatments for liver, ovarian, breast and pediatric cancer.
Collaboration is the bedrock of scientific progress.

To this end, the Samuel Waxman Cancer Research Foundation (SWCRF) is a pioneer in fostering partnerships among scientists that facilitate information exchange to advance scientific progress. Their common focus on epigenetics enables findings in one cancer category to benefit investigation in others. This community of collaborators working throughout the world has produced many FDA-approved drugs and boasts several concurrent clinical trials for potential new therapies in a range of cancers.

Researchers who form the SWCRF’s brain trust, the Institute Without Walls, laud the pivotal role the SWCRF’s philosophy of cross-institutional collaboration has played in their work and that of their colleagues.

Dr. Yu, whose affiliation with the SWCRF began eight years ago, regards the Waxman Foundation’s annual Scientific Review and Symposium a catalyst for scientific innovation. She has witnessed firsthand the impact of scientific collaboration in making discoveries and creating new approaches to treating cancer. “Collaboration with other scientists, especially those I’ve met over the years through my involvement with the Samuel Waxman Cancer Research Foundation, is a critical part of my work and achieving our shared goal,” says Dr. Yu. “The interchange of information during the SWCRF review benefits all researchers and is making a true difference for cancer patients.”

Dr. Yu sees great potential in the SWCRF’s new Partnership for Aging and Cancer Research to make impact in the ability to reach intracellular targets underlying age-related cancer by antibodies. In her own research, she is excited about her team’s establishment of a novel platform to deliver antibodies, peptides into cells and/or nucleus to target molecules that are crucial, yet non-druggable for the treatment of cancer and other devastating diseases.

Collaboration is the bedrock of scientific progress. The SWCRF is a pioneer in fostering partnerships among scientists that facilitate information exchange to advance scientific progress. Their common focus on epigenetics enables findings in one cancer category to benefit investigation in others. This community of collaborators working throughout the world has produced many FDA-approved drugs and boasts several concurrent clinical trials for potential new therapies in a range of cancers.

Kevan M. Shokat, Ph.D., is another eight-year veteran of the SWCRF Institute Without Walls. Dr. Shokat, Professor and Vice-Chair of the Department of Cellular and Molecular Pharmacology at the University of California San Francisco (UCSF), collaborates with SWCRF researchers on brain cancer. His work involves efforts to develop small molecule inhibitors of driver oncogenes that cause numerous cancers, including glioblastoma, breast cancer, and lung cancer.

Dr. Shokat and his collaborators seek to develop drug candidates that could test their hypotheses about which targets would lead to new drugs. He credits the SWCRF’s annual review with adding measurable value to his work through collaboration with fellow grantees, including his colleague at UCSF, William Weiss, M.D., Ph.D.

“I have enjoyed the focused two-day meetings where we heard the latest unpublished results from other Waxman grant recipients,” says Dr. Shokat. “This fertilized new ideas and collaborations and my close work with William Weiss, funded in part by the SWCRF, has been the most valuable collaboration in my career. I also began a collaboration with a number of other SWCRF awardees, such as Dr. Jeff Settleman, who was at Harvard at that time.”
Dr. Shokat’s work has developed Rapa-Link, an inhibitor of a mutation present in brain cancer. He and Dr. Weiss have shown that this molecule is a breakthrough in treating glioblastoma. The collaborators have licensed the compound to a start-up company in the hopes of introducing it at the clinical level.

At Memorial Sloan Kettering Cancer Center, Ross Levine, M.D., is a physician-scientist who investigates the genetic basis of malignancies in the formation of blood. He is a relative newcomer to the Institute Without Walls, having joined three years ago, and has found it to be an amazing experience enabling him to hear about the work of his fellow grantees and to receive their feedback on his research.

“It has been a tremendous experience, to be able to work with others in such an open and collaborative environment,” he notes.

“Our studies have focused on mutations in epigenetic proteins, which occur as precursor mutations, in the normal aging population, and in acute leukemias,” says Dr. Levine. “We have used support from SWCRF donors to uncover how these mutations contribute to aberrant blood cell development and to uncover approaches to target these mutations, including in patients before they develop cancer.”

Dr. Levine’s work in blood malignancies complements the SWCRF’s Aging & Cancer Research initiative, which aims to uncover the causal genetic and environmental factors that cause growing cancer mortality among people as they age.

His team’s recent work showing that pre-leukemic mutations can occur in patients with solid tumors and affect outcome opens up new questions on how, particularly in the aging setting, cancers can interact with blood cells and how this might promote cancer and cause resistance to therapies.

“The power of bringing together the world’s most brilliant cancer researchers at the SWCRF annual review cannot be underestimated,” says Samuel Waxman, M.D., founder & CEO of the Samuel Waxman Cancer Research Foundation. “Our two days of presentations provide an exchange unmatched in the world of science and we thank our donors, whose gifts support a vehicle that fosters inspiration, partnership and innovation that’s changing the cancer research landscape.”

Liver cancer is on the rise in the United States. Although a recent report from the American Cancer Society indicated that cancer-related death rates have decreased 25 percent over the past 25 years, liver cancer continues to grow, increasing by about three percent annually among women and by four percent in men. This growth is attributed to the growing presence of hepatitis C as well as alcohol consumption. The National Cancer Institute (NCI) projected that in 2016 there would be 39,230 new cases of liver and intrahepatic bile duct cancer and more than 27,000 people would die of the disease.

The Samuel Waxman Cancer Research Foundation’s (SWCRF) funded liver cancer research program at the Tisch Cancer Institute at Mount Sinai Medical Center operates at an epicenter of the cancer’s threat – New York City’s Harlem and East Harlem neighborhoods, which have among the highest incidences of liver cancer in the U.S. due to a high prevalence of chronic viral hepatitis, fatty liver and obesity linked to poor dietary habits.

Led by SWCRF grantee Josep M. Llovet, M.D., and Scott Friedman, M.D., the program has generated seminal studies elucidating the development and treatment of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA), two forms of liver cancer with rapidly rising incidence. The SWCRF has donated about $1.3 million to the Mount Sinai liver cancer program since its founding in 2003. It is the only program focused on liver cancer among 69 cancer centers and 770 programs supported by the NCI and leads the United States in liver cancer trial enrollments.

“The support of the Samuel Waxman Cancer Research Foundation and Dr. Samuel Waxman has been pivotal to the inroads our program has made over the past 14 years,” said Dr. Llovet. “We are a leader in initiating clinical trials for new liver cancer therapies and we owe much of our progress to Dr. Waxman’s contributions as a researcher and the generous donations of SWCRF supporters.”

As Director of the program, Dr. Llovet has collaborated frequently with SWCRF Founder and CEO Samuel Waxman, MD, and is a central figure in the center’s many clinical trials and international collaborations. He led a pivotal trial to test the multikinase inhibitor sorafenib in HCC and the treatment’s positive results heralded a breakthrough in the management of patients at advanced stages of the disease. This international study was recognized as the first abstract in the plenary session at the annual meeting of the American Society of Clinical Oncology in 2007, highlighted as one of the six most relevant oncology advances of that year in the scientific journal Clinical Oncology, and was published in the New England Journal of Medicine.

Dr. Llovet, a past president of the International Liver Cancer Association (ILCA) and Chair of the European guidelines of management of HCC, has served as principal investigator on several trials that positioned Mount Sinai as the leader in global recruitment of liver cancer patients in the U.S., including two sorafenib trials sponsored by Bayer Pharmaceuticals. The program has seven active studies in process for HCC with patient recruitment during the last four years exceeding 80 participants and has recruited over 200 patients for other research studies.
What inspired you to become a hematologist and scientist and how was it possible to navigate through the challenges during and following the Cultural Revolution?

I decided to be a doctor because I wanted to save people’s lives. Throughout my career, I have benefited a lot from my patients who pushed me to keep thinking and exploring. During the Cultural Revolution, I never gave up on my studies, educating myself by reading the literatures and books edited by hematologists of the US and Europe.

How did you meet Dr. Samuel Waxman?

In 1983, I attended a conference in New York City and intended to visit some academic institutions while there. A colleague of mine, Dr. Guoying Shao, was working at Dr. Samuel Waxman’s lab at Mount Sinai as a visiting scientist at the time. He introduced me to Dr. Waxman and I had the opportunity to visit his lab, thus beginning our long friendship and collaborations over 30 years.

Please describe your collaboration with Dr. Waxman on the landmark differentiation of APL with ATRA.

We began our collaboration with Dr. Waxman in the early 1980s. In 1988, our first paper reporting the dramatic effect of ATRA in treating APL was published in the journal BLOOD through the pivotal support of Dr. Waxman. In 1991, Dr. Waxman invited me to give a talk at the Mount Sinai School of Medicine to report on the progress of differentiation therapy of APL with ATRA. In 1992, I received a distinction from the SWCRF for my work on differentiation therapy. That same year, the Samuel Waxman Cancer Research Foundation Laboratory was established at the Shanghai Second Medical University (SSMU), presently Shanghai Jiao Tong University, to further advance the study of differentiation therapy, creating the first joint lab of international collaboration at SSMU. In 1997, the collaboration was further enhanced through the establishment of the SSMU and SWCRF Joint Clinical and Experimental Research Center for Cancer Differentiation Therapy at Rui-Jin Hospital. Dr. Waxman also initiated the series of international symposiums on differentiation therapy in Shanghai which have promoted the clinical and basic research of differentiation therapy. The wonderful collaboration between the East and the West has dramatically changed the clinical outcome of a malignant disease and saved the lives of thousands of patients.

How has the Shanghai Institute of Hematology (SIH) evolved during the past 30 years?

Benefiting from the rapid pace of scientific development in China, and also owing to the support from our colleagues and friends at home and abroad, the SIH has developed rapidly from a small institute to an influential academic institution in China and in the world. The Institute...
was approved to establish The Key Laboratory of Human Genome Research by the Shanghai Municipal Commission of Science and Technology in 1993 and also by the Ministry of Public Health of China in 1994. In 2001, the State Key Laboratory of Medical Genomics was approved to be established in the Institute by the Ministry of Science and Technology of China. In 2013 the first National Research Center for Translational Medicine in China was approved and the SIH research teams have played a major role at the Center. After the success of the APL treatment, we are determined to make breakthroughs in a second type of leukemia with targeted therapy.

What impact has collaboration with Dr. Waxman and the grantees of the Samuel Waxman Cancer Research Foundation had on the work of the SIH?

The work of the SIH has benefited a lot from the collaboration with Dr. Waxman and from the support from the SWCRF. First, the financial support from SWCRF in the early 1990s was very valuable at that time when there was a shortage of research funds. Second, Dr. Waxman and SWCRF contributed a lot to the training of SIH researchers, several of whom, including Zhu Chen and Sai-Juan Chen, once worked at Dr. Waxman’s lab as visiting scientists. It was in Dr. Waxman’s lab that Sai-Juan Chen cloned the fusion gene of a new chromosomal abnormality of APL which led to the identification of a novel subset of APL. Third, the SWCRF has served as an important platform for building awareness for the work of the SIH among international colleagues. This platform has brought us more opportunities for international collaborations.

What has been your experience collaborating with Prof. Zhu Chen and Prof. Sai-Juan Chen over the years?

The success of the APL treatment owes to the efforts of generations of researchers at the SIH and is a good paradigm of teamwork. My own work is mainly focused on the clinical studies of differentiation therapy of ATRA. When Zhu Chen and Sai-Juan Chen returned to China after their Ph.D. studies in France in 1989, they began to explore the cellular and molecular mechanisms of ATRA with the new techniques they had learned. In the late 1990s, they started to explore the synergistic effect between ATRA and arsenic trioxide in treating APL. Together, we designed the treatment protocol using the two drugs.

The SWCRF is committed to finding new therapies for cancer patients by studying the genetic and environmental causal factors of cancer in people as they age. Where do you foresee potential breakthrough findings in this category of scientific investigation?

I believe more important breakthroughs will be made in cancer research in the coming years and a deeper understanding of the dynamic of aging in cancer is an area of great potential for progress. However, I must say that there is still a long way to go for cancer treatment.

The Samuel Waxman Cancer Research Foundation’s philosophy of collaboration continues to have impact around the world. SWCRF grantees Shai Izraeli, M.D., Sheba Medical Center at Tel Aviv University, and Sai-Juan Chen, M.D., Ph.D., the Shanghai Institute of Hematology, made significant progress in their international collaboration on acute leukemia research launched in 2014 after winning a grant funded by the Chinese and Israeli governments.

In 2016, the Chinese group published a groundbreaking paper describing novel types of acute lymphoblastic leukemias in adolescents and young adults in the scientific journal EBioMedicine. Dr. Izraeli wrote the editorial on that research in the same journal. In May 2017 the Israeli and Chinese groups published a paper in the prestigious journal Proceedings of the National Academy of Sciences. This research discovers, for the first time, that an oncogenic signaling pathway in childhood blood cancer may also be their “Achilles’ Heel.” This research has wide scientific and therapeutic implications. Additional collaborative research between Dr. Chen’s team and Dr. Izraeli’s team is ongoing.

Thus introductions made by SWCRF founder & CEO Samuel Waxman, M.D have promoted medical research collaborations between Israel and China, enhancing possibilities for additional partnerships between China and Israel in the field of biomedicine.

1997

SWCRF and SIH introduce first successful targeted differentiation therapy for acute promyelocytic leukemia (APL) with all-trans-retinoic acid and arsenic trioxide, which increases the disease’s five-year survival rate from 25 percent to 95 percent and is now a standard treatment worldwide.

2004

The Tenth Annual Conference on Differentiation Therapy of Cancer is presented by the SWCRF and Shanghai Second Medical University in Shanghai.
The Samuel Waxman Cancer Research Foundation’s longtime connection to the fashion industry deepened further on November 10 when Dr. Samuel Waxman announced the establishment of the SWCRF Vince Camuto Memorial Cancer Research Program at the 19th annual Collaborating for a Cure Gala. Louise Camuto, Chief Creative Officer of Camuto Group, accepted the honor in memory of her husband, who passed away of prostate cancer in 2015.

The SWCRF Vince Camuto Memorial Cancer Research Program will support epigenetic research conducted collaboratively by scientists at several leading cancer research institutes to investigate the causal role of genetic and environmental factors in the rising incidence of cancer among people as they age. The U.S. Census Bureau estimates that the population of people over 65 will reach 83.7 million in 2050, almost double its 2012 population of 43.1 million. Americans diagnosed with the most prevalent cancer types are, on average, over the age of 50. As this population booms, so will the burden of cancer.

A pioneer of the 20th century footwear industry and co-founder of Nine West, Vince Camuto is credited with revolutionizing America’s affordable fashion footwear market. In 2001, Vince founded Camuto Group as a retail resource for the design, development and distribution of women’s fashion footwear. Over the next 14 years he grew the company, acquired licenses and partners, introduced brands and built Camuto Group into a global business.

Vince was an avid philanthropist, with special interest in charities that benefit women, children and families.
THANK YOU

The following donors have shared The Samuel Waxman Cancer Research Foundation’s vision and belief in collaboration by generously funding the Foundation’s Institute Without Walls in 2016.

$200,000+
Mr. and Mrs. Reuben Mark

$100,000-$199,999
Louise Camuto and the Vince Camuto Charitable Trust
Mr. and Mrs. Michael B. Nierenberg

$50,000-$99,999
The Rose M. Badgeley Charitable Trust
Mr. and Mrs. Arminio Fraga
The Max, Malie, Dr. Leonard and Bernice Laub Foundation
Mr. and Mrs. Ira Rennert
Ms. Dena K. Weiner and Mr. David Rozenholc
Ms. Mary Henry and Mr. Howard Rubin
Steven Madden, Ltd.

$20,000-$49,999
Mr. and Mrs. Joseph Ades
Alston & Bird
Jack and Florence Berlin Foundation
Mr. Brian Carosielli
Dale and Peter Claman
Clear Capital
Mr. Rick Davidson
Laura and James DeMare
Dentons
EverBank
EY
Mr. and Mrs. Kenneth Fishel
Good Hill Partners
Grandstand Sports and Memorabilia, Inc.
Hunton & Williams LLP
Jefferies LLC
KPMG Foundation
Mrs. Doralise Lama
The Tammy and Jay Levine Foundation, Inc.
Mr. and Mrs. Thomas Marano
Musa and Tom Mayer
Mr. Brian McGrath
MFA Financial Inc.
Mission Global, LLC.
Mr. Martin Migliara
Morgan Stanley
Mr. and Mrs. Randall A. Nardone
Opus Capital Market Consultants, LLC
Mara and Baron Silverstein
Skadden Arps Slate Meagher & Flom
Mr. and Mrs. Joseph G. Stetfa, Jr.
Syros Pharmaceuticals, Inc.
Mr. and Mrs. Laurence Tarica
Mr. and Mrs. Marc D. Taub
Three Strohm Sisters Family Foundation
Mr. and Mrs. Jeffrey Verschleiser
Bettina and Spencer Waxman
Weil, Gotshal & Manges, LLP
Mr. and Mrs. Matthew Zisette

$10,000-$19,999
AmTrust Title
Mr. Duane Andrews
Angelo, Gordon & Co.
Mr. and Mrs. John D. Brewer, Jr.
Mr. and Mrs. Christopher M. Callahan
Cantor Fitzgerald Relief Fund Administration
Mr. and Mrs. Peter Cherasia
Citi Business Services
Credit Suisse
Douglas Elliman Real Estate
Mr. and Mrs. Wesley Edens
Mr. and Mrs. Robert Eichler
Ms. Karen X. Fang
Jeff and Lisa Hagler
Haymakers for Hope Inc.
Hudson Bay Company
Mr. and Mrs. Marshall Insley
Mr. and Mrs. Gary Jacob
JLR Long Island, LLC
Mr. Bernard Kaminsky
Mr. and Mrs. Howard Kurz
Lafayette 148 New York
Mr. John Patrick Leo
The Lilwin Foundation
M&T Bank
Mildred & Abner Levine Family Foundation
Nomura Securities International, Inc.
Mr. Thomas L. O’Grady
Mr. and Mrs. Craig Overlander
Mr. Randy Reiff
Longhill Charitable Foundation, Inc.
Susan & Elihu Rose Foundation, Inc.
Mr. Joel R. Rotondo
Lewis and Wendy Rubin
Sequential Group
Sidley Austin LLP
The Alan B. Slifka Foundation
Mr. Sheldon Solow
Mr. Charles Sorrentino
The Surf Lodge
The Tadashi Foundation
Urban Expositions
Mr. and Mrs. Joshua B. Weintraub

$5,000-$9,999
Access Securities
Ms. Christine Arlotta and Mr. Mario Pecoraro
Mr. and Mrs. William Arnold
Barclays North America
Bernstein Capital
Capital Craftsman
Capital One
Champagne Taittinger
Digital Risk
Dr. Robert C. and Tina Sohn Foundation
Mr. and Mrs. Robert Fishbein
The G & A Foundation
The Damon Giglio Foundation
Dr. Roger Gilbert
Green Marbles
Alyssa and Cliff Greenberg
GreenbergTraurig
Heritage Strategies LLC
Mr. and Mrs. Dennis A. Herman
Mr. and Mrs. Gershon Kekst
JP Morgan
JP Morgan Real Estate Banking
Mr. and Mrs. Edward Kaminsky
Nancy Loving & David Hinkelman
Macys
Mr. Matthew McQueen
Dr. David M. Milch Family Foundation
Morgan, Lewis & Bockius LLP
People’s United Bank
Mr. George J. Petrow
Mrs. Leah P. Sanzari
Schwartz & Company, LLP
Ms. Bernice Schwartz
Gil and Debbie Schwartzberg Family Trust
Mr. Nicholas Seminara
Mr. and Mrs. Howard Shlafmitz
Mr. and Mrs. Andrew Sloves
Mr. and Mrs. Michael Smith
Mr. Nicholas P. Smith
Mr. and Mrs. Martin St. Pierre
Ms. Mary Stone and Mr. Channing Creecy
Mr. Grant Thornton
Mr. and Mrs. Mark Werner
William H. Prusoff Foundation
Norman and Rosita Winston Foundation
Mr. and Mrs. Mitchell Winter
York Restoration Corporation

$1,000-$4,999
Anonymous
Mrs. Karen Amster-Young and Mr. Benjamin Young
Mr. Zach Aronson
Ashley Carespodi
Ms. Marjorie Baldinger
Barneys
Mr. Jonathan Barrow
BBVA Compass
Mr. Solomon Berkoff
Mr. Stephen Bernstein
Mr. Alexandre Bettamio
Ms. LeeAnn Black
Bloomingdales
Tadashi Shoji & Associates, Inc.
Mrs. Linda Taub
Ms. Alex Taylor
The Twyman Family Fund
Tolis Advisors LP
TouchPOS Solutions, LLC
Mr. and Mrs. David J. Trepanier
Warburg Realty
VCS Group, LLC
Dr. and Mrs. Samuel Waxman
Mr. and Mrs. Stephen Weinstein
Wells Fargo
Mr. Howard Wewig
Mr. and Mrs. Paul Whitman
Mr. and Mrs. James Wieder
Richard and Debra Wilpon
The Janet Yaseen Foundation
Brooke and Dan Zarkowsky
Mr. Michael A. Zimmerman
$500-$999
AFAR
Ms. Kathy L. Anderson
Anikstein Family Foundation
Anonymous
Judith and Alan Appelbaum
Moris and Lana Bakhsh
Tanya and Barry Barnett
Mr. Robert H. Beinfield
Mr. Harvey Bernstein
Zoe Bernstein
Mr. Dwight Bostic
Mr. John Brady
Mr. Scott A. Carlson
The Charatan/Holm Family Foundation, Inc.
Mr. and Mrs. Lee Charles
Ms. Claudine Cher-Young
Mr. and Mrs. Ralph Cioffi
Mr. and Mrs. Harold K. Cohen
Paula and Richard Cohen
Mr. Ken Cooper smith
D’Angelico Guitars
Ms. Rosalind Devon and Mr. Sanford Batkin
Diray Media
E.W. Gordon & Company, Inc.
Epic Elevator
Mr. and Mrs. Michael Feinstein
Mr. Richard Ferrucci
New York Flooring Corp
Mr. Frank J. Folz
Mr. Thomas Geraghty
Gilman Wealth Management at Morgan Stanley
Mr. and Mrs. Michael Gleit
Ms. Judith J. Gische and Mr. Steven A. Schurman
Mr. and Mrs. Jeffery Goldman
Goodstein Development
Ms. Adrienne Gordon and Mr. Gary Herman
Mr. and Mrs. Jesse Gottlieb
Mr. Kenneth Grossman
Ms. Mimi Grotto
Mr. Eric Hadley
Amy and Bill Handwerker
Jane and Lowen Hankin
Mr. and Mrs. Robert Harrison
Ms. Rudene Haynes
Mr. Kevin Higgins
Midge and Morty Howard
Mr. Dennis P. Hughes
Mr. Naphthali Joseph
Mr. and Mrs. Bill Joseph
Freddi and Harvey Kadden
Ms. Nuri Hakanah and Mr. Werner Haase
Mr. and Mrs. Gerald P. Kaminsky
Team Systems Corporation
Mr. Eric Kaplan
Ms. Diane Katz
Mr. and Mrs. Steven Keltz
Mrs. Sharon Wilkes Kinberg and Mr. Robert Kinberg
Mr. Harvey S. Knopman
Ms. Bridget Koch
Kranz & Co
Kreitsek
Mr. and Mrs. Norman Lattman
David and Marcia Lavipour
Ms. Jeanne Lawrence
Bernard and Phyllis Leventhal
Linda Iannacci, Inc.
Ms. Erica Linden-Fineberg
Mr. Robert Mann
MANP Productions
Hyman & Ruth Mus Foundation
Mr. and Mrs. Daniel M. Nolan
Mr. James S. Olson
P & F Industries, Inc.
Ms. Gabrielle Palay
Ms. Erica D. Pearl
Pearlgreen Corporation
Mr. Dennis B. Poster
Ms. Laura Pozvolska
Protective Lining Corporation
Mr. and Mrs. Marc Puntas
RMS Fashions, Inc.
Jodi and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand Sankaranarayanan
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. J odit and Robert D. Rosenthal Family Foundation
Ms. sandy Rosenthal
Ms. Margie Rotchford
Roztayger, LLC
Mr. Richard Rubenstein
Rubie’s Costume Company, Inc.
Ms. Ali Sanders
Mr. Anand SANKARANARAYANAN
Mr. Phil Sama
Mr. Jeff Schecter
Ms. Theresa Scotto
Mr. Craig Sedmak
Mr. Neil Simon
Mr. David Smalstig
Ms. Joanne B. Snider
Mr. Greg Sobreiro
Mr. and Mrs. Michael Sokol
Barbara and Richard Solomon
Mr. Jason Spieler
Dr. Barry Sporer
Stamford Tent
Ms. Candice Stark
Ms. Claudia Taglich
Mr. and Mrs. Jeremy Tocco
Ms. Sharon M. Tomao
Mr. Moshe Vardi
Mr. and Mrs. Jonathan Weber
The Wechsler Foundation
Dr. Paul Wein
Norman Weisfeld
Mr. Aaron Welsh
Whispering Bells Foundation
Mr. and Mrs. John Woudsma
Zinon

IN-KIND DONORS
12mYDF
69 Main Gallery
AmTrust Title
Amy Bloustine Coaching
Analar Corporation
Antico Noe
Arloetta Cashmere
Arloetta Food Studio
Backyard Brine
Bareburger
Baron’s Cove
Bespoke Real Estate
BLT Steak
Blue and Cream
Blue Island Oysters
Bradford Renaissance Corp.
Café Continental
Canyon Ranch
Casa Lever
Champagne Taittinger
Chopin Vodka
Cipriani
Clarkson Avenue Crumb Cake Co.
Cloud Catering
Columbia University
Cushnie et Ochs
Cynthia Rowley
Danny Clinch
Darrell Reid
David Burke
Debra Schwartzberg
Deli catessen
DF Mavens
Diane James Home
Doña Sarita
Donna Lennard
Dragonfly by Sue North
DW Sweets
East End Car & Concierge
East Hampton Grill
Emily Cho
Endless Summer Event Catering
Erica’s Rugelach
Ezra Chowiaki
Felice
FlowerBox Wall Gardens
François Payard
Fresno Restaurant
Glam & Gio
Google Ad Grants
Hampton Coffee Company
Hampton Daze Magazine

IN-KIND DONORS
12mYDF
69 Main Gallery
AmTrust Title
Amy Bloustine Coaching
Analar Corporation
Antico Noe
Arloetta Cashmere
Arloetta Food Studio
Backyard Brine
Bareburger
Baron’s Cove
Bespoke Real Estate
BLT Steak
Blue and Cream
Blue Island Oysters
Bradford Renaissance Corp.
Café Continental
Canyon Ranch
Casa Lever
Champagne Taittinger
Chopin Vodka
Cipriani
Clarkson Avenue Crumb Cake Co.
Cloud Catering
Columbia University
Cushnie et Ochs
Cynthia Rowley
Danny Clinch
Darrell Reid
David Burke
Debra Schwartzberg
Delicatessen
DF Mavens
Diane James Home
Doña Sarita
Donna Lennard
Dragonfly by Sue North
DW Sweets
East End Car & Concierge
East Hampton Grill
Emily Cho
Endless Summer Event Catering
Erica’s Rugelach
Ezra Chowiaki
Felice
FlowerBox Wall Gardens
François Payard
Fresno Restaurant
Glam & Gio
Google Ad Grants
Hampton Coffee Company
Hampton Daze Magazine
A NOTE TO OUR SUPPORTERS

We have carefully reviewed all gifts made to the Samuel Waxman Cancer Research Foundation to ensure each gift is properly recognized. The Thank You list includes all gifts made between January 1, 2016 and December 31, 2016. Gifts mentioned exclude multiple year pledges.

We make every effort to follow the donor’s preferences when compiling the annual report list. If you would prefer to have your name listed differently in the future, please let us know. If we have made a mistake, we sincerely apologize for our error and ask you to bring it to our attention. Please contact Dan Orvieto at 646-398-5260 so the record may be corrected. Thank you.

Photo credits:
40th Anniversary Awards/Scientific Symposium by Kristen Driscoll
Collaborating for a Cure luncheon by Rob Rich/Society Allure.com
NASDAQ by Frank Padrone
A Hamptons Happening by Rob Rich/Society Allure.com
Golf tournament by Jerry Lacay
Lafayette 148 New York/Pay it Forward by Astrid Stawiarz/Getty
Tadashi/Pay it Forward courtesy Tadashi Shoji
Blow Out Breast Cancer by James Edstrom
Gala by Patrick McMullan
Cover photo by Kristen Driscoll

GIFTS WERE MADE IN HONOR OR IN MEMORY OF

Mrs. Karen Amster-Young
Mr. Ronald Bloom
Mr. Vince Camuto
Ms. Jayma Cardoso
Jean Chin, M.D.
Mr. Lou Cochet
Mr. Avi Concool
Mr. Mark Fizulich
Mr. Alan Gardener
Mrs. Donna Geraghty
Mr. William S. Gorin
Ms. Florence Harrison
Linda & Dennis Herman
Terry Hermanson
Mr. Gary Jacob
Mr. Howard Kurz
Mrs. Marcia Lavipour
Ms. Sandra Lee
Mr. Johnny Leonard
Mr. Jim McLean
Elin & Michael Nierenberg

Eli Rosenblum
Mrs. Laurie Schaffran
Ms. Lori Schlakman
Ms. Linda Shapiro
Mr. Tony Shogren
Mr. Mayer Siegel
Mr. and Mrs. Baron Silverstein
Ms. Andrea Stark
Mr. David S. Taub
Mr. Ronald Urvater
Mr. Nat Waxman
Mrs. Marion & Samuel Waxman, M.D.
Mr. Spencer Waxman
Mr. Bobby Zarin

Hampton Jam Company
Hamptons Magazine
Hans can de Bovenkamp
Harmonia Inc
Henry Chalfant
Hugo Boss
Hurricane Grill & Wings
Il Buco Vita
Insslee by Design
Italian Wine Merchants
Jackie Rogers
Jim McLean
Joey Kramer
John Varvatos
Karen Klugein
Kathy G
Kaufman Music Center
La Masseria
La Prairie
La Prairie Spa at The Ritz-Carlton New York Central Park
Lafayette 148
LDV Hospitality
Liqqshot
Loews Regency
Luckybar
Lusardi’s Restaurant
Maidstone Club
Malin and Goetz
Manna Restaurant and Bar
Maoz
Maria Bonita Salon & Spa
Michael George
Milwaukee Bucks
Minnie Rose
Mirabel Catering
Miriam Nierenberg Aronson
Montauk Brewing Company
Montauk Hard Label
My Sister’s Chef
National Academy Museum & School
Neta Sushi
New York Knicks
Nicole Miller
Noah’s
Nounós Creamery
Noyac Country Club
Old Stove Pub
Orey
Oscar de la Renta
P.C. Richard & Son
Page at 63 Main
Palm Bay International
Palm Restaurant at Hunting Inn
Patrick Sikorski
Pennpata Lao
Peter Lik
Peter Tunney
Plain T
Prive By Laurent D
Rallye Motors
Regina Kravitz
Roberto Cavalli
Roger Daltrey
Ronald J. Krowne Photography
Rowdy Hall
Roztayger
Saaz
Sag Harbor Inn
Sant Ambroeus
Sarah Ellenberg
Saratoga Water
Sen Restaurant
Serena & Lily
Silver Spoon Specialties
Skinfluence
Skinnyees
Skip Barber Racing School
Sound Aircraft Flight Enterprises
Souza’s Events
St. John
Steve Eichner
Sue North
Susan Palmer Inc
Sylvia Weinstock Cakes LLC
Tabooze
Take Two Film Academy
Talon Air
Tavern62
Tesla Motors of East Hampton
The 1770 House
The Breakers Palm Beach
The Independent
The Seafood Shop
The Sole Connection
The Surf Lodge
Tom Marano
Trattoria L’Incontro
Ubón’s BBQ
Union League Club
Valery Joseph Salon
Vegan Divas
Verve Medical Cosmetics
White’s Apothecary
Williams-Sonoma
Worth
## FINANCIAL STATEMENT

July 1, 2015 — June 30, 2016 audited

### REVENUE

<table>
<thead>
<tr>
<th>Contributions</th>
<th>$312,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Grants</td>
<td>906,000</td>
</tr>
<tr>
<td>Event Income</td>
<td>1,575,000</td>
</tr>
<tr>
<td>Investment Income</td>
<td>8,000</td>
</tr>
</tbody>
</table>

**Total Revenue**  
$2,801,000

### EXPENSE

| Program Services | 1,752,000 |
| Fundraising      | 542,000   |
| Management and General | 194,000 |

**Total Expense**  
$2,488,000

**Surplus**  
$313,000
FOUNDATION TEAM

Founder and Chief Executive Officer – Samuel Waxman, M.D.
Chief Scientific Officer – Jonathan Licht, M.D.
Chief Mission Officer – Alan Rosmarin, M.D.
Executive Director – William T. Sullivan
Director of Special Events – Bridget Stein
Director of Marketing and Communications – Edgar Trinidad
Development and Operations Coordinator – Rachel Kramer
Development Coordinator – Erica Linden-Fineberg
Scientific Advisory Board – Steven D. Gore, M.D., Lorraine Gudas, Ph.D., Robert
Hromas, M.D., Ramon Parsons, M.D., Ph.D., Nancy Speck, Ph.D., Hua Yu, Ph.D.

FOUNDATION BOARD

Chairman – Michael Nierenberg
President – Spencer Waxman
Vice Presidents – Howard Kurz, Dena K. Weiner
Treasurer – Thomas A. Conway
Secretary – Laurie L. Schaffran
Board of Directors – Kenneth Fishel, James E. Frankel, Gary Gladstein, Clifford
Greenberg, Dennis A. Herman, Linda Herman, David Hinkelstein, Gary Jacob, Robert
Kantor, Matthew Lyons, Riva Ariella Ritvo-Slifka, Lewis A. Rubin, Howard Shlafmitz,
Baron Silverstein, David S. Taub+, Samuel Waxman, M.D.
Honorary Board – Maureen Cogan, Martin L. Coyne, Mary Kantor, Abner Levine +,
Mildred Levine +, Susan W. Rose, Alan P. Safir *, Joan A. Safir *, Edwin C. Scheurer
+, Alfred J. Seaman *+, Zena Wiener
Chairman’s Council – Lawrence Altman, Dale Claman, Peter Claman, Ruth Finley,
Arminio Fraga, Betsey Johnson, Costas Kondylis, Thomas Marano, J. Jay Mauthner,
Tony M. Shogren, Tadashi Shoji, Bernard Sillins

* Past Chair  + Deceased